These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 29377669

  • 1. Discovery of Potent Benzocycloalkane Derived Diapophytoene Desaturase Inhibitors with an Enhanced Safety Profile for the Treatment of MRSA, VISA, and LRSA Infections.
    Li B, Ni S, Chen F, Mao F, Wei H, Liu Y, Zhu J, Lan L, Li J.
    ACS Infect Dis; 2018 Mar 09; 4(3):208-217. PubMed ID: 29377669
    [Abstract] [Full Text] [Related]

  • 2. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections.
    Wei H, Mao F, Ni S, Chen F, Li B, Qiu X, Hu L, Wang M, Zheng X, Zhu J, Lan L, Li J.
    Eur J Med Chem; 2018 Feb 10; 145():235-251. PubMed ID: 29328999
    [Abstract] [Full Text] [Related]

  • 3. Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
    Ni S, Wei H, Li B, Chen F, Liu Y, Chen W, Xu Y, Qiu X, Li X, Lu Y, Liu W, Hu L, Lin D, Wang M, Zheng X, Mao F, Zhu J, Lan L, Li J.
    J Med Chem; 2017 Oct 12; 60(19):8145-8159. PubMed ID: 28880552
    [Abstract] [Full Text] [Related]

  • 4. Discovery of Potent Benzofuran-Derived Diapophytoene Desaturase (CrtN) Inhibitors with Enhanced Oral Bioavailability for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections.
    Wang Y, Chen F, Di H, Xu Y, Xiao Q, Wang X, Wei H, Lu Y, Zhang L, Zhu J, Sheng C, Lan L, Li J.
    J Med Chem; 2016 Apr 14; 59(7):3215-30. PubMed ID: 26999509
    [Abstract] [Full Text] [Related]

  • 5. Discovery of Benzocycloalkane Derivatives Efficiently Blocking Bacterial Virulence for the Treatment of Methicillin-Resistant S. aureus (MRSA) Infections by Targeting Diapophytoene Desaturase (CrtN).
    Wang Y, Di H, Chen F, Xu Y, Xiao Q, Wang X, Wei H, Lu Y, Zhang L, Zhu J, Lan L, Li J.
    J Med Chem; 2016 May 26; 59(10):4831-48. PubMed ID: 27139780
    [Abstract] [Full Text] [Related]

  • 6. Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant Staphylococcus aureus.
    Ni S, Li B, Chen F, Wei H, Mao F, Liu Y, Xu Y, Qiu X, Li X, Liu W, Hu L, Ling D, Wang M, Zheng X, Zhu J, Lan L, Li J.
    ACS Med Chem Lett; 2018 Mar 08; 9(3):233-237. PubMed ID: 29541366
    [Abstract] [Full Text] [Related]

  • 7. Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
    Li B, Ni S, Mao F, Chen F, Liu Y, Wei H, Chen W, Zhu J, Lan L, Li J.
    J Med Chem; 2018 Jan 11; 61(1):224-250. PubMed ID: 29243920
    [Abstract] [Full Text] [Related]

  • 8. Dehydrosqualene Desaturase as a Novel Target for Anti-Virulence Therapy against Staphylococcus aureus.
    Gao P, Davies J, Kao RYT.
    mBio; 2017 Sep 05; 8(5):. PubMed ID: 28874472
    [Abstract] [Full Text] [Related]

  • 9. A natural inhibitor of diapophytoene desaturase attenuates methicillin-resistant Staphylococcus aureus (MRSA) pathogenicity and overcomes drug-resistance.
    Han B, Wang H, Niu X.
    Br J Pharmacol; 2024 Aug 05; 181(15):2583-2599. PubMed ID: 38604611
    [Abstract] [Full Text] [Related]

  • 10. Small-molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence.
    Chen F, Di H, Wang Y, Cao Q, Xu B, Zhang X, Yang N, Liu G, Yang CG, Xu Y, Jiang H, Lian F, Zhang N, Li J, Lan L.
    Nat Chem Biol; 2016 Mar 05; 12(3):174-9. PubMed ID: 26780405
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug 05; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 12. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ, Leonard SN, Vilay AM, Mercier RC.
    Clin Ther; 2014 Oct 01; 36(10):1334-44. PubMed ID: 25066667
    [Abstract] [Full Text] [Related]

  • 13. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G, Moellering RC.
    Clin Infect Dis; 2008 Jun 01; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [Abstract] [Full Text] [Related]

  • 14. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN.
    Clin Microbiol Infect; 2008 Mar 01; 14 Suppl 2():3-9. PubMed ID: 18226084
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
    Park YS, Shin WS, Kim SK.
    J Antimicrob Chemother; 2008 Jan 01; 61(1):163-8. PubMed ID: 17967852
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD, Pawlak J, Johnson LB.
    Int J Antimicrob Agents; 2010 Jul 01; 36(1):69-72. PubMed ID: 20413274
    [Abstract] [Full Text] [Related]

  • 17. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC.
    Int J Antimicrob Agents; 2007 Nov 01; 30(5):398-408. PubMed ID: 17888634
    [Abstract] [Full Text] [Related]

  • 18. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C, Caillon J, Le Mabecque V, Miègeville AF, Hamel A, Bugnon D, Ge JY, Potel G.
    Antimicrob Agents Chemother; 2007 Sep 01; 51(9):3397-400. PubMed ID: 17591849
    [Abstract] [Full Text] [Related]

  • 19. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM, Ward KE, LaPlante KL.
    Pharmacotherapy; 2015 Apr 01; 35(4):424-32. PubMed ID: 25884530
    [Abstract] [Full Text] [Related]

  • 20. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Micek ST.
    Clin Infect Dis; 2007 Sep 15; 45 Suppl 3():S184-90. PubMed ID: 17712745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.